The EOLO (End-of-Life Ovarian Cancer) Study: Approach to Ovarian Cancer Patients at the End of Life.
End-of-life chemotherapy is a thorny problem. This review of ovarian cancer patients, who died in the period between 2007 and 2017, recorded the frequency of chemo; the toxicity, mortality, and the most frequent palliative care measure adopted.
Of the 110 patients, 85 had undergone chemo in the last 3 months of life and 42 even had chemo during the last month.
The median overall patient survival was 52.8 months. The majority died at home, the quality of life decreased dramatically in the last 30 days.
No comments:
Post a Comment